The NPM1/MLF1 fusion related to t(3;5) is considered as an MDS-related abnormality by the 2016 WHO classification,[20] and patients with t(3;5)(q25;q35) have a 34% survival rate after 10 years, which indicates an intermediate prognosis.[9,21] Additionally, a multicenter study showed that patient characteristics of those with t(3;5) did not differ significantly from patients with normal karyotypes.[21] We reviewed and analyzed the 7 reported cases with submicroscopic deletions[8–10] (Table 2). The gene discussed is NPM1; the disease is myelodysplastic syndrome.